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Purpose: Risk stratiﬁcation of clinical stage T2c was classiﬁed as inter-
mediate risk in NCCN criteria, but it was recognized as high risk in many
other different criteria settings. Here we develop a rational nomogram to
predict pathology outcome and progression free survival for clinical stage
T2c and T2b.
Materials andMethods: From 1991 to 2010,1068men treated with radical
prostatectomy in 2 medical centers: 190 at CMUH and 878 at TVGH. Pa-
tients enrolled in this cohort had complete information of preoperative
serum PSA level, biopsy Gleason score (GS) and clinical stage determined
by rectal digital examination. All prostatectomy specimens were inked on
surface, ﬁxed and series step sections with 3-4 mm from apex to base. A
logistic regression model was used to estimate the probability of organ-
conﬁned disease (OC), extra-prostate extension (EPE)), seminal vesicle
involvement (SVI) and positive node (PN). In this cohort included 235
clinical stage T2b and 190 stage T2c. Follwing prostatectomy, all patients
were not received any adjuvant therapy until PSA failure.
Results: The mean age of the study population was 66.8 years (range 40
to 83 years). The ﬁnal pathologic stage demonstrated that 48.7%, 48.2%,
and 15.3% had OC, EPE and SVI, respectively. A nomogram on the basis of
this logistic regression model appears in each tables of variables different
PSA level, GS, and clinical stage contributed to prediction of pathologic
stage according to logistic regression. Both stage T2c and T2b demon-
strated the similar probability of pathological outcome regarding to OC,
EPE, SVI and NI in each PSA level and Gleason score. The combination of
preoperative variables predicted pathologic stage better than any single
variable individually. There are 74 patients (39%) had PSA level >20 ng/ml
in stage T2c compare to 57 patients (24%) in T2b. The incidence of
Gleason score 8-10 was also higher in stage T2c than in stage T2b (22 vs
16 %). There are 82 cases (35%) in stage T2b compare to 96 (51 %) even-
tually stratiﬁed as high risk disease. The progression free survival of stage
T2c was signiﬁcant inferior to the stage T2b (33 vs 58%) in 5 years and (25
vs 53%) in 10 years.
Conclusion: We have constructed a nomogram for clinical stage T2b and
T2c base on Asia population for predict pathological outcome with
reasonable accuracy and potentially be applied in high risk patients. Stage
T2c demonstrated as higher percentage of high risk variables (PSA
>20 ng/ml and Gleason score>7) that resulted in lower progression free
survival.http://dx.doi.org/10.1016/j.urols.2015.06.004IPD02:
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Purpose: Recently, local control of primary prostate cancer in patients
with metastasis has been attracting attention. However, the clinical sig-
niﬁcance of such strategies has not yet been well established. The aim of
this retrospective study was to determine whether local radiotherapy
confers survival beneﬁt in patients with metastatic prostate cancer.
Materials and Methods: Between February 1993 and March 2000, 102
patients with prostate cancer attending our institution received intra-
operative radiotherapy (IORT). Among them, 16 patients with stage D1
prostate cancer according to the Whitmore-Jewett staging system (D1
IORT group), and 32 patients with stage D2 (M1a or M1b) prostate cancer
according to the 7th UICC TNM staging system (D2 IORT group), were
included in this study as IORT group. Their treatment comprised: (a) IORT
for the prostate with a dose of 25 or 30 Gy given in a fraction after the
dissection of pelvic lymph node; (b) external beam radiotherapy of the
prostate (30Gy given in 10 fractions) commencing about 1 week post-
operatively; (c) neoadjuvant and/or adjuvant endocrine treatment. Overall
survival (OS) and cause-speciﬁc survival (CSS) were calculated and factors
affecting survival were assessed by multivariate analysis. In addition, OS
and CSS of the D2 IORT group were compared to those of the 38 patients
with stage D2 (M1a or M1b) prostate cancer attending our institution
between April 2000 and December 2005 who did not undergo any local
therapy (D2 control group).
Results:Median follow-up period was 71 months for the IORT group (D1 +
D2), and 49 months for the D2 control group. Among the IORT group, 18
patients (37.5%) died of prostate cancer. There were no statistically sig-
niﬁcant differences of clinical features between the D2 IORT group and the
D2 control group. The 5-/10-year CSS, and OS of the IORT group were 75.9/
52.7%, and 61.0/31.7%, respectively. The 5-/10-year CSS, and OS of the
control group were 45.8/33.5%, and 42.1/30.8%, respectively. CSS of the D2
IORT group was signiﬁcantly longer than that of the D2 control group
(P ¼ 0.030). Univariate and multivariate reduced rank regression analysis
showed that grade 4 by extent of disease grading system (EOD 4) (HR: 7.51,
P ¼ 0.012), and non-regional lymph node metastasis (HR: 5.58, P ¼ 0.027)
were statistically signiﬁcant prognostic factors. Patients without these
unfavorable factors (EOD4/non-regional lymph node metastasis) had
signiﬁcantly longer OS and CSS than those with any of them (P < 0.001).
The 5-year OS/CSS were 71.6/90.6% in the former group, and 27.3/31.2%, in
the latter group.
Conclusions: Local radiotherapy of the prostate in patients with meta-
static prostate cancer may contribute to better survival provided that the
patients are without any of the identiﬁed unfavorable factors (EOD4/non-
regional lymph node metastasis).
